Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GSK Files Marketing Authorisation Application For Benlysta
Benlysta is an investigational human monoclonal antibody drug. It is the first in a new class of drugs called BLyS-specific inhibitors that recognise and inhibit the biological activity
Benlysta is an investigational human monoclonal antibody drug. It is the first in a new class of drugs called BLyS-specific inhibitors that recognise and inhibit the biological activity
With IND approval, Ritter is permitted to initiate a Phase IIa clinical trial of RP-G28, directly assessing its safety, tolerability and effectiveness in humans. RP-G28’s IND approval confirms
AVI BioPharma has filed a current report on Form 8-K with the US Securities and Exchange Commission. AVI-7100 was previously designated AVI-7367 and has been renumbered by AVI
Keryx Biopharma has presented the data in the pediatric solid tumor poster discussion session held at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO)
PFC said that access to Maccabi’s multidimensional clinical database and patient registries are expected to reduce the risks of clinical research and shorten time to market. PFC and
Aptar Pharma organisation is expected to be implemented progressively during 2010, and will be fully operational in the beginning of 2011. Pfeiffer and Valois said that the new
Taro Pharma’s Granisetron tablets is a prescription product used for the prevention of nausea and vomiting associated with chemotherapy and radiation treatment and is bioequivalent to Hoffman-La Roche’s
RXi Pharma claimed that one of the challenges in developing RNAi-based therapeutics is finding ways to deliver them to their target while keeping them fully active. RXi’s proprietary
Pharmalucence is a privately-held, employee-owned company specializing in the production and marketing of radiopharmaceuticals and the furnishing of contract drug formulation, analytical methods development and production services. The
Abbott has partnered with Fujirebio Diagnostics in the development of the assay. The Architect HE4 assay is also approved for use in Europe, as well as in other